2023-09-12 20:09:11
During the next European Oncology Congress (Esmo), which will be held at the end of October in Madrid, two full sessions will be exclusively devoted to therapeutic vaccines against cancer. angellodeco – stock.adobe.com
DECRYPTION – The promising results of a French start-up against lung cancer are part of intense research to develop effective injections against several types of tumors.
« In a few years, we will perhaps look at the year 2023 as the start of a new era in cancer care. » Nicolas Poirier, general director of OSE Immunotherapeutics, savors « the runaway » which his company is the subject of, with positive results from a vaccine against lung cancer.
Its results also shine the spotlight on a nascent market which is already sparking competition between players in the pharmaceutical industry. It took a few months to change the situation. Last May, the German BioNTech – which made itself known for its RNA vaccine against Covid, with Pfizer – published the promising results of a phase 1 study, conducted with the Swiss Roche, of a vaccine targeting pancreatic cancer. In December 2022, Moderna announced positive results from a phase 2 trial against melanoma. The two biotechs, which have built their success around messenger RNA technology, have since their creation caused cancer…
This article is reserved for subscribers. You have 80% left to discover.
Flash Sale -70%
Offer available until September 25. Without engagement.
Already subscribed? Log in
#race #started #biotechs #laboratories